Active Vimentin (VIM)
- Product No.APB040Hu01
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
- Traits Freeze-dried powder
- Purity> 97%
- Isoelectric Point5.2
- ApplicationsCell culture; Activity Assays.
- DownloadInstruction Manual
- UOM 10µg50µg 200µg 1mg 5mg
- FOB
US$ 224
For more details, please contact local distributors! US$ 560 US$ 1120 US$ 3360 US$ 8400
ACTIVITY TEST
Vimentin (VIM) is a type III intermediate filament (IF) protein that is expressed in mesenchymal cells.vimentin is the major cytoskeletal component of mesenchymal cells. Because of this, vimentin is often used as a marker of mesenchymally-derived cells or cells undergoing an epithelial-to-mesenchymal transition (EMT) during both normal development and metastatic progression. Besides, Keratin 20 (KRT20) has been identified as an interactor of VIM, thus a binding ELISA assay was conducted to detect the interaction of recombinant human VIM and recombinant human KRT20. Briefly, VIM were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μl then transferred to KRT20-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-VIM pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µl stop solution to the wells and read at 450nm immediately. The binding activity of VIM and KRT20 was shown in Figure 1, and this effect was in a dose dependent manner.
USAGE
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
STORAGE
Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
- BCA Protein Quantification Kit
- Molecular Mass Marker for Protein
- Monoclonal Antibody Customized Service
- Polyclonal Antibody Customized Service
- Protein Activity Test Experiment Service
- Electrophoretic Mobility Shift Assay (EMSA) Experiment Service
- Buffer
- Lentivirus Packaging Experiment Service
- Adenovirus Packaging Experiment Service
- Real Time PCR Experimental Service
- Spike RBD Protein (S-RBD)
- Protein G
- Protein A
Magazine | Citations |
Cancer Epidemiology, Biomarkers & Prevention | Aberrant Vimentin Methylation Is Characteristic of Breast Cancer pubmed:22315367 |
Scientific Reports | Glyoxalase 1-knockdown in human aortic endothelial cells - effect on the proteome andendothelial function estimates. pubmed:27898103 |
Journal of Proteomics | HtrA3 is a cellular partner of cytoskeleton proteins and TCP1α chaperonin Pubmed:29477555 |
Journal of Biological Chemistry | Growth hormone induces Notch1 signaling in podocytes and contributes to proteinuria in diabetic nephropathy Pubmed: 31511328 |
American Journal of Transplantation | Extracellular vesicles derived from injured vascular tissue promote the formation of tertiary lymphoid structures in vascular allografts Pubmed: 31729155 |
Lung | Is Vimentin the Cause or Effect of Obstructive Sleep Apnea Development? Pubmed: 32088750 |
Cell Biol Toxicol | ZNF471 modulates EMT and functions as methylation regulated tumor suppressor with diagnostic and prognostic significance in cervical cancer 33566221 |
CELL BIOLOGY AND TOXICOLOGY | Metastatic suppression by DOC2B is mediated by inhibition of epithelial-mesenchymal transition and induction of senescence 33758996 |
Comparison of Vimentin Levels Between Preeclamptic and Normotensive Pregnant Women | |
Advanced glycation end-products associate with podocytopathy in type II diabetic patients | |
Non-POU Domain-Containing Octamer-Binding (NONO) Protein Stability Regulated by PIN1 is Crucial for Breast Cancer Tumorigenicity Via the MAPK/β … |
Catalog No. | Related products for research use of Homo sapiens (Human) Organism species | Applications (RESEARCH USE ONLY!) |
RPB040Hu02 | Recombinant Vimentin (VIM) | Positive Control; Immunogen; SDS-PAGE; WB. |
APB040Hu01 | Active Vimentin (VIM) | Cell culture; Activity Assays. |
RPB040Hu01 | Recombinant Vimentin (VIM) | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB040Hu02 | Polyclonal Antibody to Vimentin (VIM) | WB; IHC; ICC; IP. |
PAB040Hu01 | Polyclonal Antibody to Vimentin (VIM) | WB; IHC; ICC/IF |
LAB040Hu71 | Biotin-Linked Polyclonal Antibody to Vimentin (VIM) | WB; IHC; ICC. |
MAB040Hu24 | Monoclonal Antibody to Vimentin (VIM) | WB; IHC |
MAB040Hu25 | Monoclonal Antibody to Vimentin (VIM) | WB; IHC; IF |
MAB040Hu21 | Monoclonal Antibody to Vimentin (VIM) | WB; IHC; ICC; IP. |
MAB040Hu23 | Monoclonal Antibody to Vimentin (VIM) | WB; IHC; ICC; IP. |
MAB040Hu27 | Monoclonal Antibody to Vimentin (VIM) | WB; IHC; ICC; IP. |
MAB040Hu22 | Monoclonal Antibody to Vimentin (VIM) | WB; IHC; ICC/IF |
FAB040Hu02 | Anti-Vimentin (VIM) Monoclonal Antibody | Flow cytometry. |
FAB040Hu06 | Anti-Vimentin (VIM) Monoclonal Antibody | Flow cytometry. |
FAB040Hu04 | Anti-Vimentin (VIM) Monoclonal Antibody | Flow cytometry. |
FAB040Hu08 | Anti-Vimentin (VIM) Monoclonal Antibody | Flow cytometry. |
SEB040Hu | ELISA Kit for Vimentin (VIM) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB040Hu | Multiplex Assay Kit for Vimentin (VIM) ,etc. by FLIA (Flow Luminescence Immunoassay) | FLIA Kit for Antigen Detection. |
KSB040Hu01 | ELISA Kit DIY Materials for Vimentin (VIM) | Main materials for "Do It (ELISA Kit) Yourself". |